Catalyst Pharmaceuticals (CPRX) EBITDA Margin (2018 - 2026)

Catalyst Pharmaceuticals has reported EBITDA Margin for 9 years, with the latest figure at 42.67% in Q1 2026.

• For the quarter ending Q1 2026, EBITDA Margin rose 261.0% year-over-year to 42.67%; the trailing twelve-month figure through Mar 2026 stood at 37.08% (up 17.0% YoY), and the FY2025 full-year result was 36.38%, up 304.0% from the prior year.
• EBITDA Margin for Q1 2026 stood at 42.67%, up from 34.53% in the prior quarter.
• The five-year high for EBITDA Margin was 42.67% in Q1 2026, with the low at 29.96% in Q3 2023.
• Historically, EBITDA Margin has averaged 32.13% across 5 years, with a median of 35.55% in 2025.
• Annual changes were most pronounced in 2023 — EBITDA Margin sank 6998 bps — and 2024, when it surged 6406 bps.
• Catalyst Pharmaceuticals' EBITDA Margin stood at 41.91% in 2022, then fell by 25 bps to 31.51% in 2023, then gained by 25 bps to 39.49% in 2024, then fell by 13 bps to 34.53% in 2025, then advanced by 24 bps to 42.67% in 2026.
• The last three EBITDA Margin figures came in at 42.67% (Q1 2026), 34.53% (Q4 2025), and 35.55% (Q3 2025), per Business Quant data.